Last updated on April 2019

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: HEPATOCELLULAR CARCINOMA
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participants must have confirmed diagnosis of hepatocellular carcinoma (HCC) with any of the following criteria:
  • Histologically or cytologically confirmed diagnosis of HCC, excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors
  • Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases criteria, including cirrhosis of any etiology and/or chronic hepatitis B or C infection
  • Part 1: HCC for which no other appropriate therapy is available; Part 2: No prior systemic therapy for advanced/unresectable HCC
  • Participants categorized to stage B (not applicable for transarterial chemoembolization), or stage C based on Barcelona Clinic Liver Cancer staging system
  • Child-Pugh score A
  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 to 1
  • Age 20 years at the time of informed consent

Exclusion Criteria:

  • Active co-infection with hepatitis B and hepatitis C
  • Participants with any active, known, or suspected autoimmune disease
  • Participants being treated with drugs that strongly inhibit or induce CYP3A4 and that may be possibly used during this study
  • Females who are breastfeeding or pregnant

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.